Navigation Links
Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
Date:3/30/2009

- Lorcaserin Very Well Tolerated Throughout Two-Year Study

- Conference Call Scheduled for Today at 8:30 a.m. EDT

SAN DIEGO, March 30, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today positive top-line results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight management. Statistical significance (p<0.0001) was achieved on all three of the hierarchically ordered co-primary endpoints for patients treated with lorcaserin versus placebo. Treatment with lorcaserin was generally very well tolerated. An assessment of echocardiograms indicates no apparent drug-related effect on the development of US Food and Drug Administration (FDA)-defined valvulopathy over the two-year treatment period.

Primary Endpoint Analysis

The hierarchically ordered endpoints were the proportion of patients achieving 5% or greater weight loss after 12 months, the difference in mean weight loss compared to placebo after 12 months, and the proportion of patients achieving 10% or greater weight loss after 12 months. Compared to placebo, using an intent-to-treat last observation carried forward (ITT-LOCF) analysis, treatment with lorcaserin was associated with highly statistically significant (p<0.0001) categorical and average weight loss from baseline after 12 months:

  • 47.5% of lorcaserin patients lost greater than or equal to 5% of their body weight from baseline compared to 20.3% in the placebo group. This result satisfies the efficacy benchmark in the most recent FDA draft guidance.
  • Average weight loss of 5.8% of body weight, or 12.7 pounds, was achieved in the
    '/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Arena Pharmaceuticals Announces Public Offering of Common Stock
3. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
4. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
7. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
9. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
10. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
11. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... ... , ... Natural Rest contains a unique mixture of vitamins and herbs that ... help to improve mood disorders and anxiety. Like all other Creative Medical Health products, ... of regenerative medicine conducted by Dr. Amit Patel of the University of Utah, one ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... today that Executive Vice President Jeff Fernandez will lead the expansion of global ... of cosmeceutical and skin care experience having spent the last 25 years working ...
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare Medical, LLC, ... treatment of prostate cancer, has announced the roll-out of its newest technology – ... in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use at the ...
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at Estrella ... Colleges , will be hosting a Job Expo to provide a professional, open venue ... Expo has expanded to much more than just a typical job and career fair. ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, ... Applied Research Foundation (Meso Foundation) will present an educational program titled “Asbestos and ... and lasts through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2
... validity of Purdue patents; Receives limited license rights ... ST. LOUIS, June 9 KV Pharmaceutical Company (NYSE: ... it has entered into a settlement agreement with Purdue Pharma ... lawsuit between the two companies. Under the terms of ...
... early in the course of disease is the best approach ... acute myeloid leukemia (AML), according to a new analysis of ... published in the June 10 issue of the Journal ... Cancer Institute and other institutions, provide new guidelines for treatment ...
... , WASHINGTON, June 9 The "Blue Dog Coalition," a ... oppose a strong public option to for-profit health insurers, took ... insurance and drug industries according to Consumer Watchdog. , ... Landrieu (D-LA) now opposes the public option. Landrieu received ...
... expert says, , TUESDAY, June 9 (HealthDay News) -- ... women as their pregnancy progresses, a new Brazilian study ... to 80 percent of moms-to-be suffering heartburn, stomach pain ... worsen over time, and women who avoid taking medicine ...
... PEMBROKE, Bermuda, June 9 Allied World Assurance,Company (U.S.) ... Ltd (NYSE: AWH ), today announced an ... in the United States. The,complimentary service, called "Strategic Response(SM)," ... resources in the,event of a catastrophe. , ...
... New Dialysis Patients Making a Difference in Cutting Patient Mortality ... (NYSE: DVA ), a leading provider of kidney ... today commended Kidney Care Partners for launching the Performance Excellence ... Partners - a coalition of patient advocates, dialysis professionals, care ...
Cached Medicine News:Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 2Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 3Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 4Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 5Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 6Health News:Study IDs benefit of donor SCT for adults with acute myeloid leukemia 2Health News:Will Insurer & Drug Money Leash the 'Blue Dogs'? 2Health News:Will Insurer & Drug Money Leash the 'Blue Dogs'? 3Health News:Will Insurer & Drug Money Leash the 'Blue Dogs'? 4Health News: Acupuncture May Relieve Heartburn In Pregnancy 2Health News: Acupuncture May Relieve Heartburn In Pregnancy 3Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 2Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 3Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 2Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 3
(Date:8/28/2015)... Aug. 28, 2015 Research ... of the "Investigation Report on China,s Ranibizumab Market, ... by Novartis, ranibizumab was approved by CFDA to treat ... only Lucentis, a product of Novartis, is available in ... first self- developed drug for the treatment of wet ...
(Date:8/28/2015)... , Aug. 28, 2015  Perrigo Company plc ... it has completed the acquisition of leading OTC brands ... €200 million. The transaction is a clear demonstration of ... Company,s leading European distribution network spanning 36 countries.  ... C. Papa commented, "We are excited to complete ...
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... Essential Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by ... , Asia-Pacific , and Rest of ... by MarketsandMarkets, The global market for Eubiotics was valued at ... USD 7.05 Billion by 2020, at a CAGR of 7.4% ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
Angled shafts with 12 mm scaled jaws. 1 mm teeth on one jaw fit into holes on the other jaw. Slide lock and serrated handle with polished finish. Right. Most popular size or model....
Angled 13.5 mm adjustable blades. Teeth in lower jaws fit into holes in upper jaws. Grooves in lower jaw for passage of suture needles. Round knurled handle with polished finish....
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Delicate # 4...
Medicine Products: